Abbott’s nutritional products business has China in its rearview mirror as a pediatric market, progress on restoring infant formula manufacturing capacity, nearly 4% sales growth in its latest quarter and signs of tailwinds ahead.
The firm on 19 April reported 3.8% first-quarter growth in total nutritional sales to $1.97bn, driven by 19.9% growth in total US sales to $812m as infant formula and other...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?